AGY vs. INDV, AMYT, APH, ANCR, VLG, DNL, EAH, STX, PXS, and CHLL
Should you be buying Allergy Therapeutics stock or one of its competitors? The main competitors of Allergy Therapeutics include Indivior (INDV), Amryt Pharma (AMYT), Alliance Pharma (APH), Animalcare Group (ANCR), Venture Life Group (VLG), Diurnal Group (DNL), ECO Animal Health Group (EAH), Shield Therapeutics (STX), Provexis (PXS), and Chill Brands Group (CHLL). These companies are all part of the "drug manufacturers - specialty & generic" industry.
Allergy Therapeutics vs.
Indivior (LON:INDV) and Allergy Therapeutics (LON:AGY) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, media sentiment, community ranking, institutional ownership, valuation, earnings, risk, profitability and dividends.
In the previous week, Indivior's average media sentiment score of 0.00 equaled Allergy Therapeutics'average media sentiment score.
86.0% of Indivior shares are owned by institutional investors. 3.4% of Indivior shares are owned by company insiders. Comparatively, 93.0% of Allergy Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Indivior has a beta of 0.19, indicating that its share price is 81% less volatile than the S&P 500. Comparatively, Allergy Therapeutics has a beta of 1.4, indicating that its share price is 40% more volatile than the S&P 500.
Indivior has a net margin of -0.17% compared to Allergy Therapeutics' net margin of -72.86%. Indivior's return on equity of -0.77% beat Allergy Therapeutics' return on equity.
Indivior has higher revenue and earnings than Allergy Therapeutics. Indivior is trading at a lower price-to-earnings ratio than Allergy Therapeutics, indicating that it is currently the more affordable of the two stocks.
Indivior currently has a consensus price target of GBX 1,650, suggesting a potential upside of 96.66%. Given Indivior's stronger consensus rating and higher probable upside, equities research analysts plainly believe Indivior is more favorable than Allergy Therapeutics.
Indivior received 198 more outperform votes than Allergy Therapeutics when rated by MarketBeat users. Likewise, 80.43% of users gave Indivior an outperform vote while only 77.97% of users gave Allergy Therapeutics an outperform vote.
Summary
Indivior beats Allergy Therapeutics on 11 of the 16 factors compared between the two stocks.
Get Allergy Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for AGY and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Allergy Therapeutics Competitors List
Related Companies and Tools
This page (LON:AGY) was last updated on 5/23/2025 by MarketBeat.com Staff
Buy AGY Stock Free AGY Stock Alerts